Stroke prevention in atrial fibrillation: Current status and near-future directions

American Journal of Medicine

Volumn 124, Issue 9, 2011, Pages 793-799

  De Caterina, Raffaele ^a   Hylek, Elaine M ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Antithrombotic therapy; Atrial fibrillation; Stroke; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BETRIXABAN; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; TECARFARIN; WARFARIN;

AGE; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EMBOLISM; EMBOLISM PREVENTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SEX; STROKE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VASCULAR DISEASE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTITHROMBINS; ASPIRIN; ATRIAL FIBRILLATION; DRUG INTERACTIONS; DRUG TOXICITY; DRUGS, INVESTIGATIONAL; FACTOR XA; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; VITAMIN K;

EID: 80052031525     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.03.013     Document Type: Review

References (44)

1. J. Heeringa, D.A. van der Kuip, and A. Hofman Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur Heart J 27 2006 949 953
2. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
3. H.S. Jorgensen, H. Nakayama, and J. Reith Acute stroke with atrial fibrillation The Copenhagen Stroke Study Stroke 27 1996 1765 1769 (Pubitemid 26332501)
4. M. Hughes, and G.Y. Lip Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data Thromb Haemost 99 2008 295 304 (Pubitemid 351230959)
5. R. De Caterina, S. Husted, and L. Wallentin Anticoagulants in heart disease: current status and perspectives Eur Heart J 28 2007 880 913 (Pubitemid 47343588)
6. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867 (Pubitemid 351650486)
7. S. Connolly, J. Pogue, and R. Hart Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
8. S.J. Connolly, J. Pogue, and J. Eikelboom Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 2008 2029 2037
9. S.J. Connolly, J. Pogue, and R.G. Hart Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
10. E.M. Hylek, C. Evans-Molina, and C. Shea Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2007 2689 2696 (Pubitemid 46842784)
11. A.J. Camm, P. Kirchhof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
12. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870 (Pubitemid 32537350)
13. G.Y. Lip, L.H. Rasmussen, and S.B. Olsson Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists Eur Heart J 30 2009 2897 2907
14. V. Fuster, L.E. Ryden, and D.S. Cannom ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 2006 e257 e354
15. D.E. Singer, G.W. Albers, and J.E. Dalen Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 2008 546S 592S (Pubitemid 351892972)
16. Stroke Risk in Atrial Fibrillation Working Group Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation Stroke 39 2008 1901 1910
17. M.C. Fang, A.S. Go, and Y. Chang Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation J Am Coll Cardiol 51 2008 810 815 (Pubitemid 351253746)
18. G.Y. Lip, R. Nieuwlaat, and R. Pisters Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation Chest 137 2010 263 272
19. J. Mant, F.D. Hobbs, and K. Fletcher Warfarin vs aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 2007 493 503 (Pubitemid 47212371)
20. J.S. Healey, R.G. Hart, and J. Pogue Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) Stroke 39 2008 1482 1486
21. B.H. Lee, J.S. Park, and J.H. Park The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1 J Cardiovasc Electrophysiol 21 2010 501 507
22. L. Gorin, L. Fauchier, and E. Nonin Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1 Thromb Haemost 103 2010 833 840
23. A.L. Waldo, R.C. Becker, V.F. Tapson, and K.J. Colgan Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation J Am Coll Cardiol 46 2005 1729 1736 (Pubitemid 41531631)
24. R. Nieuwlaat, A. Capucci, and A.J. Camm Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation Eur Heart J 26 2005 2422 2434 (Pubitemid 41552972)
25. J.Y. Le Heuzey, G. Breithardt, and J. Camm Profile of patients according to chosen therapeutic strategy in the RecordAF global registry on atrial fibrillation management Circulation 118 Abs 4634 2008 S923
26. E.M. Hylek, S.J. Skates, M.A. Sheehan, and D.E. Singer An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation N Engl J Med 335 1996 540 546 (Pubitemid 26272308)
27. J. Hirsh, V. Fuster, J. Ansell, and J.L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J Am Coll Cardiol 41 2003 1633 1652 (Pubitemid 36543387)
28. J. Ansell, J. Hirsh, and E. Hylek Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 2008 160S 198S (Pubitemid 351892967)
29. P.J. Lin Reviewing the reality: why we need to change Eur Heart J Suppl 2005 E15 E20
30. D. Deplanque, D. Leys, and L. Parnetti Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management Main results of the SAFE II study Br J Clin Pharmacol 57 2004 798 806 (Pubitemid 38748048)
31. H. Robert-Ebadi, G. Le Gal, and M. Righini Use of anticoagulants in elderly patients: practical recommendations Clin Interv Aging 4 2009 165 177
32. L. Friberg, N. Hammar, and M. Ringh Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study) Eur Heart J 27 2006 1954 1964 (Pubitemid 44297370)
33. G.C. Flaker, J. Pogue, and S. Yusuf Cognitive function and anticoagulation control in patients with atrial fibrillation Circ Cardiovasc Qual Outcomes 3 2010 277 283
34. J.L. Halperin What can ongoing clinical trials of anticoagulants demonstrate? J Cardiovasc Med (Hagerstown) 10 2009 610 615
35. M.R. Lassen, and V. Laux Emergence of new oral antithrombotics: a critical appraisal of their clinical potential Vasc Health Risk Manag 4 2008 1373 1386
36. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698 (Pubitemid 37468318)
37. G.W. Albers, H.C. Diener, and L. Frison Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690 698
38. H.C. Diener Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation Pooled analysis from the SPORTIF III and V studies Cerebrovasc Dis 21 2006 279 293
39. W.M. Lee, D. Larrey, and R. Olsson Hepatic findings in long-term clinical trials of ximelagatran Drug Saf 28 2005 351 370 (Pubitemid 40545769)
40. AstraZeneca AstraZeneca decides to withdraw Exanta™ http://www.astrazeneca.com/Media/Press-releases/Article/20060214AstraZeneca- Decides-to-Withdraw-Exanta
41. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran vs warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
42. S.J. Connolly, J. Eikelboom, and C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
43. D.J. Ellis, M.H. Usman, and P.G. Milner The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation Circulation 120 2009 1029 1035 2 p following 1035
44. J.W. Eikelboom, M. O'Donnell, and S. Yusuf Rationale and design of AVERROES: apixaban vs acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment Am Heart J 159 2010 348 e1 353 e1